
Borja HernÃ;ndez-Breijo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3655141/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma. World Journal of Gastroenterology, 2011, 17, 3899.	3.3	30
2	EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2023, 82, 65-73.	0.9	24
3	Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease. Biomarkers, 2017, 22, 133-144.	1.9	21
4	RNAiâ€mediated silencing of insulin receptor substrateâ€4 enhances actinomycin D―and tumor necrosis factorâ€î±â€induced cell death in hepatocarcinoma cancer cell lines. Journal of Cellular Biochemistry, 2009, 108, 1292-1301.	2.6	18
5	Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus. Autoimmunity Reviews, 2019, 18, 102372.	5.8	14
6	The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Clinical Rheumatology, 2019, 38, 949-954.	2.2	13
7	Azathioprine desensitizes liver cancer cells to insulin-like growth factor 1 and causes apoptosis when it is combined with bafilomycin A1. Toxicology and Applied Pharmacology, 2013, 272, 568-578.	2.8	12
8	Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. Biochemical Pharmacology, 2016, 122, 33-41.	4.4	12
9	Is the Autophagy Induced by Thiopurines Beneficial or Deleterious?. Current Drug Metabolism, 2012, 13, 1267-1276.	1.2	11
10	Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. Arthritis Research and Therapy, 2019, 21, 66.	3.5	10
11	Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. RMD Open, 2022, 8, e002216.	3.8	10
12	Dendritic Nanotheranostic for the Delivery of Infliximab: A Potential Carrier in Rheumatoid Arthritis Therapy. International Journal of Molecular Sciences, 2020, 21, 9101.	4.1	6
13	Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. European Journal of Gastroenterology and Hepatology, 2020, 32, 588-596.	1.6	6
14	Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis. Frontiers in Immunology, 2020, 11, 1913.	4.8	5
15	BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors. Scientific Reports, 2021, 11, 11632.	3.3	5
16	538 Correlation Between Adalimumab Serum Levels and Remission After the Induction Phase in Crohn's Disease Patients. Gastroenterology, 2015, 148, S-107-S-108.	1.3	4
17	Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity. Biomedicines, 2022, 10, 727.	3.2	4
18	Effect of Infliximab in oxidised serum albumin levels during experimental colitis. Biomarkers, 2014, 19, 693-701.	1.9	3

#	Article	IF	CITATIONS
19	Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis. Frontiers in Medicine, 2021, 8, 692557.	2.6	3
20	Tu1291 Infliximab Serum Levels Do Not Predict Remission After the Induction Phase in Crohn's Disease Patients. Gastroenterology, 2015, 148, S-849.	1.3	2
21	FRI0399â€INFLIXIMAB TROUGH LEVELS AND DISEASE ACTIVITY PREDICT EARLY CLINICAL RESPONSE IN PATIEN WITH AXIAL SPONDYLOARHTRITIS. , 2019, , .	TS	2
22	Extracellular allograft inflammatory factor-1 (AIF-1) potentiates Th1 cell differentiation and inhibits Treg response in human peripheral blood mononuclear cells from normal subjects. Human Immunology, 2020, 81, 91-100.	2.4	2
23	Serum leptin concentration is associated with the attainment of clinical outcomes in patients with axial spondyloarthritis treated with TNF inhibitors. Clinical and Experimental Rheumatology, 2022, , .	0.8	2
24	Tu1292 Quantification of the Concentration of Antibodies Against Infliximab (IFX) in Human Serum Using a Pure Antibody As Calibrator. Gastroenterology, 2015, 148, S-850.	1.3	1
25	Low serum calprotectin levels correlate with the presence of biological drugs after the first year of treatment in patients with rheumatoid arthritis. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 538-540.	1.2	1
26	Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481986784.	3.2	1
27	Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. Scientific Reports, 2020, 10, 17099.	3.3	1
28	Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral NaÃ⁻ve B Cells in Patients With Rheumatoid Arthritis. Frontiers in Medicine, 2021, 8, 683990.	2.6	1
29	510 INSULIN RECEPTOR SUBSTRATE-4 INHIBITS AKT/PKB ACTIVITY FORMING A TERNARY COMPLEX WITH SHIP AND EGFR. EFFECT ON HEPG2 CANCER CELL MOTILITY. Journal of Hepatology, 2009, 50, S190.	3.7	0
30	710 AZATHIOPRINE PRODUCES OXIDIZATION OF 53 KDA AND 67 KDA PROTEINS AND INDUCES MITOCHONDRIAL DEPENDENT APOPTOSIS IN GSH DEPLETED HEPG2 CELLS. Journal of Hepatology, 2009, 50, S260.	3.7	0
31	493 AZATHIOPRINE PRODUCES AUTOPHAGY THROUGH ERK/MTOR/P70S6K PATHWAY IN HEPG2 CELLS. Journal of Hepatology, 2011, 54, S202.	3.7	0
32	Mo2002 Desensitization of the IGF-I Receptor Signal Transduction in Rat Colon With Experimental Colitis. Gastroenterology, 2012, 142, S-717-S-718.	1.3	0
33	Su1211 The Autophagy Produced by Azathioprine in HEPC2 Cells Leads to Apoptotic Cell Death Due to Inhibition With Bafilomycin A1. Gastroenterology, 2012, 142, S-452.	1.3	0
34	Su1212 Azathioprine Produces Autophagy in Hepatoblastoma Cells by Desensitization to Insulin-Like Growth Factor 1 (IGF-1). Gastroenterology, 2012, 142, S-452.	1.3	0
35	Tu1647 Effect of Infliximab Treatment on an Ulcerative Colitis Experimental Model in Rat. Gastroenterology, 2013, 144, S-814.	1.3	0
36	P080 Effect of insulin like growth factor-1 on experimental colitis. Journal of Crohn's and Colitis, 2013, 7, S41.	1.3	0

Borja HernÃindez-Breijo

#	Article	IF	CITATIONS
37	Tu1705 Role of Allograft Inflammatory Factor 1 (AIF-1) in Inflammatory Bowel Disease. Gastroenterology, 2014, 146, S-822.	1.3	0
38	Su1199 Allograft Inflammatory Factor-1 (AIF-1) Stimulates Th1 Differentiation of Human T-Cells and Protects Them From Apoptosis. Gastroenterology, 2015, 148, S-435.	1.3	0
39	Mo1713 Binding of Infliximab to Human Serum Exosomes. Gastroenterology, 2015, 148, S-692.	1.3	0
40	Sa1919 Regulation of G1/S Checkpoint by Insulin Receptor Substrate-4 in Colon Cancer Cells and Its Possible Involvement in Colorectal Cancer. Gastroenterology, 2015, 148, S-354-S-355.	1.3	0
41	Tu1293 Soluble TNF Serum Levels During the Induction Phase in Crohn's Disease Patients With Anti-TNF Treatment. Gastroenterology, 2015, 148, S-850.	1.3	0
42	SAT0141â€Optimal circulating adalimumab levels range associated with good clinical response in rheumatoid arthritis patients. , 2017, , .		0
43	AB0375â€The effect of concomitant use of methotrexate on the clinical activity in patients with rheumatoid arthritis under ANTI-TNFTHERAPY. , 2017, , .		0
44	FRI0194â€Use of gloresponsetm NF-κB-RE-LUC2P HEK293 cells to monitor drug and anti-drug antibody levels in serum. , 2017, , .		0
45	THU0661â€Clinical relevance of detecting anti-adalimumab antibodies with a drug-tolerant assay. , 2017, , ·		0
46	Differential blood cellular profile in patients with moderate-to-severe psoriasis treated with classical systemic therapies: a step forward in personalized medicine. British Journal of Dermatology, 2018, 179, 765-766.	1.5	0
47	AB0201â€Association between baseline calprotectin serum levels and response to biological therapy in patients with rheumatoid arthritis. , 2018, , .		0
48	P816 Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. Journal of Crohn's and Colitis, 2019, 13, S529-S531.	1.3	0
49	AB0409â€B CELLS PROFILE AS A BIOMARKER FOR EARLY IDENTIFICATION OF OPTIMAL RESPONDERS TO TNF INHIBITORS IN RHEUMATOID ARTHRITIS. , 2019, , .		0
50	FRI0095â€CHANGES IN B CELL PROFILE AS INDICATOR OF CLINICAL REMISSION TO TNF INHIBITORS IN PATIEN WITH RHEUMATOID ARTHRITIS. , 2019, , .	TS	0
51	148â€Antimalarial agents and other immunosuppressants influence BAFF levels in opposite directions in patients with systemic lupus erythematosus. , 2019, , .		0
52	FRI0198â€ANTIMALARIAL AGENTS DIMINISH WHILE METHOTREXATE, AZATHIOPRINE AND MYCOPHENOLIC AG INCREASE BAFF LEVELS IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .	CID	0
53	Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failure. Seminars in Arthritis and Rheumatism, 2020, 50, E1-E2.	3.4	0
54	POS0623â€CYTOKINE PRODUCTION BY BLOOD LYMPHOCYTES DEFINES A PROFILE ASSOCIATED WITH NON-REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNF INHIBITORS. Annals of the Rheumatic Diseases, 2021, 80, 549.2-550.	0.9	0

#	Article	IF	CITATIONS
55	POSO617â€ANTI INFLIXIMAB ANTIBODIES DETECTED BY A DRUG TOLERANT ASSAY ARE FREQUENT BUT, IN MA CASES, WITHOUT RELEVANT CLINICAL SIGNIFICANCE. Annals of the Rheumatic Diseases, 2021, 80, 546.1-546.	ΝΥ 0.9	0
56	Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis. Scandinavian Journal of Rheumatology, 2021, , 1-8.	1.1	0
57	ABO418â€The effect of concomitant methotrexate on serum tnf inhibitors levels and clinical response in patients with rheumatoid arthritis is dose dependent and greater than other dmards. , 2018, , .		0
58	AB0916â€Efficacy and predictive factors of clinical response to tnf inhibitors in patients with axial and peripheral psoriatic arthritis. , 2018, , .		0
59	FRI0186â€Concomitant csdmards influence clinical response to tnf inhibitors only in overweight patients with axial spondyloarthritis. , 2018, , .		0
60	FRI0102â€Reduction of antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with previous failure to infliximab or adalimumab. , 2018, , .		0
61	FRI0582â€GM-CSF PRODUCED BY CD4+ T CELLS AS A MARKER OF CLINICAL REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNF INHIBITORS. Annals of the Rheumatic Diseases, 2020, 79, 895.2-895.	0.9	0
62	SAT0084â€SERUM ADIPOKINES PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNF-INHIBITORS. Annals of the Rheumatic Diseases, 2020, 79, 976.2-976.	0.9	0